cDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer


City of Hope Comprehensive Cancer Center, Duarte, CA; Memorial Sloan Kettering Cancer Center, New York, NY; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; UCSF-Norris Comprehensive Cancer Center, Los Angeles, CA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT; Mount Sinai School of Medicine, New York, NY; Wayne State University, Detroit, MI; Viterbo Scientifico-Borgonovo per il Studio di Aste del Timone, Mediolan, Italy; University of Michigan Comprehensive Cancer Center, University of Michigan Health Care, Ann Arbor, MI; Sarah Cannon Research Institute, Nashville, TN, USA; QED Therapeutics Inc, San Francisco, CA; Texas School of Medicine of USC, Los Angeles, CA, USA

conclusion

The safety profile of infigratinib is predictable, manageable, and consistent with on-target inhibition of FGFR-3.

The authors would like to thank the following:


References

The authors would like to thank the following:

Patients

Conclusions

The safety profile of infigratinib is predictable, manageable, and consistent with on-target inhibition of FGFR-3.

The higher risk of progressive disease in patients with detectable FGFR2 mutations in cfDNA warrants further study.

The authors would like to thank the following:

Patients participating in the trial and their families, the investigators, and staff at participating centers.

Lisa Miller (Miller Medical Communications) for provision of medical writing support for this poster. This work was funded by QED Therapeutics.

Acknowledgements

The authors would like to thank the following:

The study is a phase 1b/2 trial of infigratinib (QD-1802) in patients with metastatic urothelial cancer (mUC). The study is designed to test the efficacy and safety of infigratinib when dosed as a single agent in patients with mUC bearing an FGFR3 mutation identified by next-generation sequencing on cfDNA, and at the time of subsequent analysis.

Table 4. TEAEs in >20% of patients (any grade)

<table>
<thead>
<tr>
<th>Event</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>50 (75.4)</td>
<td>18 (26.9)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Blood creatinine increased</td>
<td>26 (38.8)</td>
<td>18 (26.9)</td>
<td>11 (16.4)</td>
<td>2 (2.9)</td>
</tr>
<tr>
<td>Blood potassium decreased</td>
<td>23 (34.3)</td>
<td>19 (28.4)</td>
<td>12 (17.9)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Blood phosphorus decreased</td>
<td>21 (31.3)</td>
<td>18 (26.9)</td>
<td>9 (13.4)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Blood sodium decreased</td>
<td>26 (38.8)</td>
<td>21 (31.3)</td>
<td>8 (11.9)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Blood urea increased</td>
<td>27 (40.3)</td>
<td>21 (31.3)</td>
<td>9 (13.4)</td>
<td>1 (1.5)</td>
</tr>
</tbody>
</table>

The safety profile of infigratinib is predictable, manageable, and consistent with on-target inhibition of FGFR-3.

The higher risk of progressive disease in patients with detectable FGFR2 mutations in cfDNA warrants further study.

Acknowledgements

The authors would like to thank the following:

Patients participating in the trial and their families, the investigators, and staff at participating centers.

Lisa Miller (Miller Medical Communications) for provision of medical writing support for this poster. This work was funded by QED Therapeutics.

References
